Transcytosis - An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery

Numerous nano drug delivery systems have been developed for preclinical cancer research in the past 15 years with the hope for a fundamental change in oncology. The robust nanotherapeutic research has yielded early-stage clinical products as exemplified by the FDA-approved nano formulations (Abraxan...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiangsheng, Jiang, Jinhong, Meng, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857052/
https://www.ncbi.nlm.nih.gov/pubmed/31754378
http://dx.doi.org/10.7150/thno.38587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857052/
https://www.ncbi.nlm.nih.gov/pubmed/31754378
http://dx.doi.org/10.7150/thno.38587

Ejemplares similares